Evidence map›Paper›PMID 36264388›Full record

ArticleCellular and molecular life sciences : CMLS2022

Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA.

Miriam Morente-López, Rocío Mato-Basalo, Sergio Lucio-Gallego, Lucía Silva-Fernández, Alba González-Rodríguez, Fco Javier De Toro, Juan A Fafián-Labora, María C Arufe

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Miriam Morente-López *Grupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain.
Rocío Mato-Basalo *Grupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain.
Sergio Lucio-GallegoGrupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain.
Lucía Silva-FernándezGrupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain.
Alba González-RodríguezGrupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain.
Fco Javier De ToroGrupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain.
Juan A Fafián-LaboraGrupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain. juan.labora@udc.es.
María C ArufeGrupo de Terapia Celular y Medicina Regenerativa, Dpto. de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidade da Coruña, INIBIC-CHUAC, CICA, 15006, A Coruña, Spain. maria.arufe@udc.es.ORCID http://orcid.org/0000-0003-3725-0743
Universidade da Coruña · ES

Funding

Instituto de Salud Carlos III PI20/00497Secretaria Xeral de Investigación e Desenvolvemento, Xunta de Galicia ED481D-2021-020
6 · The paper itself

Abstract

Osteoarthritis (OA) is closely linked to the increase in the number of senescent cells in joint tissues, and the senescence-associated secretory phenotype (SASP) is implicated in cartilage degradation. In the last decade, extracellular vesicles (EV) in combination with the use of miRNAs to modify post-transcriptional expressions of multiple genes have shown their utility in new therapies to treat inflammatory diseases. This work delves into the anti-inflammatory effect of extracellular vesicles derived from mesenchymal stem cells (MSC) previously modified to inhibit the expression of miR-21. We compare the efficacy of two treatments, MSC with their miR-21 inhibited through lentiviral transfection and their EV, against inflammation in a new OA animal model. The modified MSC and their EV were intraperitoneally injected in an OA animal model twice. One month after treatment, we checked which therapy was the most effective to reduce inflammation compared with animals untreated. Treated OA model sera were analyzed for cytokines and chemokines. Subsequently, different organs were analyzed to validate the results obtained. EV were the most effective treatment to reduce chemokines and cytokines in serum of OA animals as well as SASP, in their organs checked by proteomic and genomic techniques, compared with MSC alone in a statistically significant way. In conclusion, MSC-miR-21

Indexed as

Mesenchymal Stem CellsMicroRNAsOsteoarthritisAnimalsAnti-Inflammatory AgentsChemokinesCytokinesDisease Models, AnimalHumansInflammationProteomicsUmbilical CordAnti-Inflammatory AgentsChemokinesCytokinesMicroRNAsExtracellular vesicles (EV)Mesenchymal stem cells (MSC)miR-21-5p (miR-21)Syndecan-1 (SDC1)

Identifiers

PMID36264388
PMCPMC9584990
OpenAlexW4306873840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.